Invivyd Q4 PEMGARDA revenue $17.2M (+31% QoQ); VYD2311 DECLARATION trial fully enrolled, top-line mid-2026

Invivyd, Inc.

Q4 2025 PEMGARDA net revenue $17.2M (up 25% YoY, 31% QoQ); FY2025 revenue $53.4M vs $25.4M in 2024.
Cash and equivalents $226.7M at Dec 31, 2025; raised over $200M in 2H 2025.
FY2025 net loss $52.5M ($0.30/share) vs $169.9M ($1.43/share) in 2024; R&D expenses fell to $38.3M.
DECLARATION Phase 3 trial for VYD2311 fully enrolled; IDMC allows pregnant/breastfeeding women; top-line data expected mid-2026.
Appointed Michael Mina, M.D., Ph.D., as CMO; Fast Track designation for VYD2311 granted Dec 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.